Antiretroviral therapy is recommended for all HIV-infected individuals regardless of CD4 count to decrease morbidity and mortality associated with HIV infection.
Goals of antiretroviral treatment are suppression of viral load for maximum possible duration, restore & preserve immunologic function, reduce HIV-related morbidity & mortality and prevent HIV transmission.
Urgent initiation of antiretroviral treatment is recommended in the following individuals: pregnant women, patients w/ HIV with coinfections (HBV, HCV, active tuberculosis), AIDS-defining illness, HIV-associated nephropathy, low CD4 counts, acute opportunistic infections and HIV HBV with evidence of chronic liver disease.
Access to pre-exposure prophylaxis (PrEP) may be expanded through pharmacies to reach racial minorities of men who have sex with men (MSM) with the highest need but are not being reached, suggest the results of a US study.
Treatment with the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) leads to sustained viral suppression through 4 years with no treatment-emergent resistance in treatment-naïve people living with HIV (PWH), according to a long-term study presented at IAS 2021.
About four-fifths of heavily treated HIV patients with multidrug resistance have achieved viral suppression with the investigational long-acting subcutaneous lenacapavir (LEN) used in combination with an optimized antiretroviral (ART) regimen, according to the 26-week data from the ongoing phase II/III CAPELLA study.
Use of feminizing hormone therapy (FHT) does not appear to cancel the effect of oral pre-exposure prophylaxis (PrEP) in transgender women at high risk of HIV, according to data from the PrEParadas study presented at the 11th International AIDS Society Conference (IAS 2021).
Among virologically suppressed people living with HIV (PLHIV), lack of adherence to antiretroviral therapy (ART) may be linked to an increased risk of death unrelated to cardiovascular disease (CVD), according to results of the Swiss HIV Cohort Study (SHCS).
New drug applications approved by US FDA as of 16-31 January 2021 which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.